L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Rius Medical mission is to make its proprietary highly innovative platform available at year 2 to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.
Waldachtal, Baden-Württemberg, Germany
Send a message
Dear Business Angels,
I hope this email finds you well. Here are the February 2020 latest updates:
 The Rius Medical project is available to all investors, as published on EuroQuity and European Investment Project Portal (EIPP) 1. From EuroQuity, the Resource Link Consulting Group expressed its interest in Rius Medical and issued a Memorandum of Understanding. Resource Link Consulting Group agreed on a total investment value of 1.000.000 € against 20% ownership as a silent partner to Rius Medical.
 Optional: Rius Medical is issuing to Business Angels up to 50.000 € Convertible Loan at a discounted rate of 0,50 € per share. A 14.000 € investment with EXIT opportunity at year 2 (i.e. December 2021) implies 1.512.000 € financial benefits for FIVE products, if not 294.000 € financial benefits for TWO products being transformational improvements on biopharmaceutical.
Many thanks and warmest regards,
Founder and CEO
The Business Plan “red blood cells for drug delivery” depicts an investment opportunity with strong return on Investment at year 3. For early investors’ review of Rius Medical, here in the Business Plan you have all information provided to investors interested in forming a syndicate.
Gaining traction in cell therapy is gene engineering. You see that in CAR-T /CAR-NK cell therapies with viral vectors addition of CAR genes. And you can see that also with iPS derived cell therapies like Bayer acquisition of BlueRock Therapeutics 1. Rius Medical takes advantage of that and goes THREE steps further. (1) Yes we add genes for cell therapies. (2) Furthermore, what is unique in our approach is that we are the only company using a “master template” that significantly reduce Industry Challenges relative to our competitors e.g. Erytech Pharma or Rubius Therapeutics. (3) The three of us combine (Rius Medical, Erytech Pharma and Rubius Therapeutics) have the same product - red blood cells for drug delivery. What makes Rius Medical unique is that our gene engineering approach brings the only solution to Industry Challenges (i.e. enables market entry with strong profit earnings). Despite successful phase III clinical data 2 with acute lymphoblastic leukemia, Erytech Pharma discontinued it’s Leukaemia program in June 2018 3 and instead shifted focus to solid tumor, now under phase III clinical studies in pancreatic cancer.
Simply having a higher price tag is not attracting customers. Market approved CAR-T cells by Novartis and Gilead Sciences illustrate that 4. It is working - proof of concept is established in engineering stem cells and there are thousands of research scientists around the world doing the same thing I did in stem cells research, i.e. culture stem cells into cellular therapies that work under academia settings! Those that were able to get financing are demonstrating that in clinical studies (again Erytech Pharma and Rubius Therapeutics). Nonetheless Industry Challenges 5 are a problem we as scientists face in developing cell therapies. That’s why I left academia to start Rius Medical that offers a solution to the Industry Challenges. The business opportunity here with FIVE assets, brings 54 million euro Return on Investment to investors at year 3 on up to 1 million euro equity capital investment.
It would be helpful to know how early investors wish to move forward. After all, there is no innovation without collaboration! Are you against forming a syndicate of investors?
Many thanks and warmest regards,
Rius Medical based in Germany has a technology to upgrade French base company Erytech Pharma using red blood cells for drug delivery of therapeutic protein L-Asparaginase, thus targeting multiple cancers.
To the disappointment of Recordati an investor to Erytech Pharma, Erytech Pharma discontinued it’s Leukaemia program in June 2018 despite successful phase III clinical data with Acute Lymphoblastic Leukemia (ALL) and instead shifted focus to solid tumor, now under phase III clinical studies. Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products. The solution, Rius Medical technology engineers stem cells into therapeutic products and provides a Business-to-Business solution to France-based Erytech Pharma for upgraded red blood cells that do more than simply carry oxygen.
Furthermore, from the perspective of French pharmaceutical company Servier Laboratories, seeking opportunities in FIVE areas of research and development being cardiovascular diseases, cancer, diabetes, neuropsychiatric diseases like multiple sclerosis and immune-inflammatory diseases; Rius Medical platform technology for the delivery of therapeutic protein encapsulated in red blood cells addresses all FIVE of them. The upgrade there is with antigen-loaded red blood cells against Autoimmune diseases.
As a young company not doing incremental improvements, Rius Medical develops a platform technology to engineer stem cells for next generation therapeutics as core business. Rius Medical mission is to make its highly innovative platform technology available at 3 years to pharmaceutical and biotech partners. In addressing Ageing and Ageing-related diseases such as cardiovascular disease, Rius Medical is a Deep tech company bringing innovation to an aging society with Deep Tech for healthcare.
This is the path of Rius Medical making the French economy more competitive by boosting French companies Erytech Pharma and Servier Laboratories in bringing their products to market following an upgrade in technology. For the French economy, that translates into local Job creation and a healthier work force within an ageing population.
Denis Demarais (BSc)
Founder, CEO and Chief Scientific Officer
Start in 31 August 2016
31 August 2016
registration with the commercial register of Stuttgart local court under folio HRB 757947
to be continued ...